Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1421-1440 of 1,694 trials

Alzheimer’s Disease: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve memory and daily activities in patients with mild cognitive impairment and Alzheimer's disease. This study will also assess its effects on brain health and quality of life.

Alzheimer's Disease1-2 yearsEfficacy phase (II)Standard MedicinesNeurologyPsychiatry

Multiple Myeloma: Isatuximab Treatment Study

We are studying a new treatment combination for elderly patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see if this approach improves disease control and safety compared to standard treatments.

Newly Diagnosed Multiple Myeloma in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

NSTEMI Treatment: Aspirin vs. Aspirin and Fondaparinux

We are comparing the effects of aspirin alone to a combination of aspirin and fondaparinux in patients with NSTEMI. This study aims to see which treatment is more effective and safer before invasive procedures.

Non-ST-Elevation Myocardial Infarction (NSTEMI)>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Colorectal Cancer: MK-1084 Treatment Study

We are testing a new treatment combining MK-1084, cetuximab, and chemotherapy for patients with advanced colorectal cancer. The goal is to see if this combination is safer and more effective than standard treatments.

Metastatic Colorectal CancerKRAS Mutation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Unruptured Intracranial Aneurysms: Low-Dose Aspirin and Blood Pressure Management

We are studying whether a treatment plan with low-dose aspirin and strict blood pressure control can lower the risk of aneurysm rupture or growth in patients with unruptured intracranial aneurysms. This trial compares this approach to standard care to see if it offers better outcomes.

Unruptured Intradural Aneurysm>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCardiologyNeurology

Sinusitis Treatment: Azithromycin Study

We are testing whether a three-month course of azithromycin improves quality of life for adults with idiopathic purulent oedematous sinusitis. The study will compare its effects to a placebo and evaluate treatment tolerance.

Bacterial SinusitisChronic Sinusitis>2 yearsConfirmation phase (III)Investigational MedicinesOtolaryngology

Higher Risk Myelodysplastic Syndrome: Lisaftoclax with Azacitidine

We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.

Higher Risk Myelodysplastic SyndromeConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology

Knee Osteoarthritis: KBP-336 Medication Study

We are testing a new medication for obese individuals with knee osteoarthritis to see if it helps reduce weight and pain. The study will also look at other symptoms and overall safety compared to a placebo.

Knee OsteoarthritisObesity6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Psoriatic Arthritis: JNJ-77242113 Study

We are testing a new medication for people with active psoriatic arthritis who have used other biologic treatments. The study aims to see if it can reduce symptoms better than a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Myeloma Treatment: Elranatamab vs. Daratumumab

We are studying whether elranatamab combined with lenalidomide helps patients with newly diagnosed myeloma maintain remission better than daratumumab with lenalidomide after a transplant. This trial will also assess safety and quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Advanced Liver Cancer: CS1003 with Lenvatinib

We are studying a new treatment combined with lenvatinib for people with advanced liver cancer. The trial compares this combination to a placebo with lenvatinib to see which is more effective and safe.

Unresectable Advanced Liver Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHepatologyOncology

TOASST Study: Comparing Steroid Withdrawal Methods

We are studying whether stopping glucocorticoids suddenly is as safe as tapering them for patients with inflammatory disorders. This research may help improve treatment strategies and patient outcomes.

Inflammatory or Autoimmune Disorders>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Statin Therapy for Frail Older Adults After Stroke

We are studying whether starting statin medication helps frail individuals aged 70 and older who have had a recent stroke or transient ischemic attack. The goal is to see if it improves heart health and quality of life.

Ischemic Stroke and Transient Ischemic Attack>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Ovarian Cancer: Olaparib and Bevacizumab Study

We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.

Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Multiple Myeloma: New Treatment Combinations

We are studying a combination of new medications for people with newly diagnosed multiple myeloma who can undergo a transplant. The goal is to evaluate their safety and effectiveness in improving treatment outcomes.

Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pancreas and Kidney Transplant: Sirolimus vs. Mycophenolate Mofetil

We are comparing two medications to see which one may reduce the risk of hernias after simultaneous pancreas and kidney transplants in people with type 1 diabetes. We also want to understand their effects on diabetes complications.

End-stage Kidney Disease in Type 1 DiabetesTransplantation ComplicationsSimultaneous Pancreas and Kidney Transplantation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal MedicineNephrologyOncologyUrology

Dental Implants: Antibiotic Use in Bone Augmentation

We are studying whether short or long-term antibiotic use is more effective during dental implant surgery. This trial will also look at how these antibiotics affect bacteria in the mouth and gut.

Need for Oral Bone Augmentation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Sacubitril/Valsartan for Arrhythmogenic Right Ventricular Cardiomyopathy

We are studying whether sacubitril/valsartan can help prevent disease progression in patients with ARVC. This trial aims to assess its effects on heart tissue changes.

Arrhythmogenic Cardiomyopathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology